Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Liver transplantation offers the only definite cure for cirrhosis but lacking donors is problem. Stem cell therapy is attractive in this setting. In this study, we aimed to explore the safety and efficacy of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cell (PBMC) in cirrhotic patients. Methods: A total of nine decompensated cirrhotic patients were randomized into three groups: group 1 (n = 3) was control group, group 2 (n = 3) received granulocyte-colony stimulating factor (G-CSF) mobilization for 3 days, and group 3 (n = 3) received G-CSF mobilized PBMCs by leukapheresis and PBMC transplantation through ultrasound-guided percutaneous portal vein puncture. Liver function and clinical features were evaluated. Results: At baseline, the Child-Turcotte-Pugh and the model for end-stage liver disease scores were comparable in study groups. Compared with group 1, there was a tendency to improve liver function in group 3 at 6 months after treatment. Treatment was tolerable and no complications were encountered related to the G-CSF mobilization or percutaneous portal administration of PBMCs. Imaging studies showed patent portal veins at the end of the study period. Conclusions: Autologous PBMC transplantation through ultrasound-guided percutaneous portal vein puncture could be considered as a safe alternative treatment for decompensated cirrhotic patients.
Abstract
Background/Aims: Liver transplantation offers the only definite cure for cirrhosis but lacking donors is problem. Stem cell therapy is attractive in this setting. In this study, we aimed to explore the safety and efficacy of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cell (PBMC) in cirrhotic patients. Methods: A total of nine decompensated cirrhotic patients were randomized into three groups: group 1 (n = 3) was control group, group 2 (n = 3) received granulocyte-colony stimulating factor (G-CSF) mobilization for 3 days, and group 3 (n = 3) received G-CSF mobilized PBMCs by leukapheresis and PBMC transplantation through ultrasound-guided percutaneous portal vein puncture. Liver function and clinical features were evaluated. Results: At baseline, the Child-Turcotte-Pugh and the model for end-stage liver disease scores were comparable in study groups. Compared with group 1, there was a tendency to improve liver function in group 3 at 6 months after treatment. Treatment was tolerable and no complications were encountered related to the G-CSF mobilization or percutaneous portal administration of PBMCs. Imaging studies showed patent portal veins at the end of the study period. Conclusions: Autologous PBMC transplantation through ultrasound-guided percutaneous portal vein puncture could be considered as a safe alternative treatment for decompensated cirrhotic patients.
참고문헌 (39)
- Shim JH, "Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrh", J Hepatol, 52, pp.176~182 (2010)
- Han Y, "Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy", Cytotherapy, 10, pp.390~396 (2008)
- Pai M, "Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis", Am J Gastroenterol, 103, pp.1952~1958 (2008)
- Lagasse E, "Purified hematopoietic stem cells can differentiate into hepatocytes in vivo", Nat Med, 6, pp.1229~1234 (2000)
- Korbling M, "Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells", N Engl J Med, 346, pp.738~746 (2002)
- Theise ND, "Liver from bone marrow in humans", Hepatology, 32, pp.11~16 (2000)
- Alison MR, "Hepatocytes from non-hepatic adult stem cells", Nature, 406, pp.257~ (2000)
- Grove JE, "Plasticity of bone marrow-derived stem cells", Stem Cells, 22, pp.487~500 (2004)
- Terai S, "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy", Stem Cells, 24, pp.2292~2298 (2006)
- Yannaki E, "Last-ing amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells", Exp Hematol, 34, pp.1583~1587 (2006)
- am Esch JS 2nd, "Portal application of autologous CD133+ bone marrow cells to the liver:a novel concept to support hepatic regeneration", Stem Cells, 23, pp.463~470 (2005)
- Gordon MY, "Characterization and clinical application of human CD34+ stem", progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor, 2006, pp.24, 1822~1830
- Yan L, "Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes", Am J Hematol, 82, pp.949~954 (2007)
- Suresh K., "An overview of randomization techniques: an unbiased assessment of outcome in clinical research", J Hum Reprod Sci, 4, pp.8~11 (2011)
- Levicar N, "Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease", Cell Prolif, 41(Suppl 1), pp.115~125 (2008)
- Kharaziha P, "Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial", Eur J Gastroenterol Hepatol, 21, pp.1199~1205 (2009)
- Campard D, "Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells", Gastroenterology, 134, pp.833~848 (2008)
- Teramoto K, "Hepatocyte differentiation from embryonic stem cells and umbilical cord blood cells", J Hepatobiliary Pancreat Surg, 12, pp.196~202 (2005)
- Piscaglia AC, "Stem cell-based therapies for liver diseases: state of the art and new perspectives", Stem Cells Int, 2010, pp.259461~ (2010)
- Margini C, "Bone marrow derived stem cells for the treatment of endstage liver disease", World J Gastroenterol, 20, pp.9098~9105 (2014)
- Lorenzini S, "Stem cells for end stage liver disease: how far have we got?", World J Gastroenterol, 14, pp.4593~4599 (2008)
- Fausto N., "Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells", Hepatology, 39, pp.1477~1487 (2004)
- Mallet VO, "Mobilizing stem cells to repair liver after surgery: dream or reality?", J Hepatol, 43, pp.754~756 (2005)
- de Wynter EA, "CD34+AC133+ cells isolated from cord blood are highly enriched in longterm culture-initiating cells, NOD", SCID-repopulating cells and dendritic cell progenitors, 1998, pp.16, 387~396
- Mizunaga Y, "Granulocyte colony-stimulating factor and interleukin-1β are important cytokines in repair of the cirrhotic liver after bone marrow cell infusion: comparison of humans and model mice", Cell Transplant, 21, pp.2363~2375 (2012)
- Jin SZ, "Granulocyte colony-stimulating factor enhances bone marrow mononuclear cell homing to the liver in a mouse model of acute hepatic injury", Dig Dis Sci, 55, pp.2805~2813 (2010)
- Picardi M, "Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization", Haematologica, 88, pp.794~800 (2003)
- Falzetti F, "Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor", Lancet, 353, pp.555~ (1999)
- Lorenzini S, "Stem cell mobilization and collection in patients with liver cirrhosis", Aliment Pharmacol Ther, 27, pp.932~939 (2008)
- Gaia S, "Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease", J Hepatol, 45, pp.13~19 (2006)
- Di Campli C, "Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure", Dig Liver Dis, 39, pp.1071~1076 (2007)
- Spahr L, "Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial", Hepatology, 48, pp.221~229 (2008)
- Kisseleva T, "The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis", J Hepatol, 56, pp.965~972 (2012)
- Lorenzini S, "Regenerative medicine and liver injury: what role for bone marrow derived stem cells?", Curr Stem Cell Res Ther, 2, pp.83~88 (2007)
- Jang YY, "Hematopoietic stem cells convert into liver cells within days without fusion", Nat Cell Biol, 6, pp.532~539 (2004)
- Wang X, "Cell fusion is the principal source of bone-marrow-derived hepatocytes", Nature, 422, pp.897~901 (2003)
- Sakaida I, "Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice", Hepatology, 40, pp.1304~1311 (2004)
- Wang L, "Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells", Gastroenterology, 143, pp.1555.e2~1563.e2 (2012)
- Qi X, "Clinical outcomes of the transplantation of stem cells from various human tissue sources in the management of liver cirrhosis: a systematic review and meta-analysis", Curr Stem Cell Res Ther, 10, pp.166~180 (2015)